Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Technology appraisal guidance
Reference number: TA563
Published:
Evidence
Documents containing the evidence that was used to develop the recommendations.